ValuEngine upgraded shares of AbbVie (NYSE:ABBV) from a hold rating to a buy rating in a report published on Friday.

Several other analysts have also commented on ABBV. Cowen raised AbbVie from a market perform rating to an outperform rating and boosted their price target for the company from $91.17 to $105.00 in a research note on Wednesday, October 11th. UBS Group reissued a neutral rating on shares of AbbVie in a research note on Friday, October 13th. Barclays boosted their price objective on AbbVie to $90.00 and gave the stock an equal weight rating in a research note on Friday, October 13th. Jefferies Group boosted their price objective on AbbVie from $107.00 to $115.00 and gave the stock a buy rating in a research note on Monday, October 16th. Finally, Zacks Investment Research raised AbbVie from a hold rating to a buy rating and set a $102.00 price objective on the stock in a research note on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $117.26.

Shares of AbbVie (ABBV) opened at $115.17 on Friday. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. The company has a market capitalization of $183,590.00, a price-to-earnings ratio of 27.95, a P/E/G ratio of 1.11 and a beta of 1.61. AbbVie has a one year low of $60.05 and a one year high of $125.86.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion for the quarter, compared to analyst estimates of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. AbbVie’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.20 EPS. equities analysts forecast that AbbVie will post 7.46 earnings per share for the current year.

In other news, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the sale, the senior vice president now owns 113,118 shares in the company, valued at $11,136,467.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Laura J. Schumacher sold 145,510 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $96.71, for a total value of $14,072,272.10. The disclosure for this sale can be found here. In the last three months, insiders sold 476,376 shares of company stock worth $45,580,873. Insiders own 0.23% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Formidable Asset Management LLC increased its holdings in AbbVie by 0.3% in the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after purchasing an additional 10 shares during the last quarter. WealthTrust Axiom LLC increased its holdings in AbbVie by 0.3% in the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after purchasing an additional 15 shares during the last quarter. Abner Herrman & Brock LLC increased its holdings in AbbVie by 0.3% in the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after purchasing an additional 18 shares during the last quarter. St. Louis Trust Co increased its holdings in AbbVie by 0.7% in the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after purchasing an additional 23 shares during the last quarter. Finally, TRUE Private Wealth Advisors increased its holdings in AbbVie by 0.6% in the second quarter. TRUE Private Wealth Advisors now owns 4,814 shares of the company’s stock valued at $349,000 after purchasing an additional 27 shares during the last quarter. Institutional investors own 69.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “AbbVie (ABBV) Upgraded to Buy at ValuEngine” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://theolympiareport.com/2018/02/03/abbvie-abbv-upgraded-to-buy-at-valuengine.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.